Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in Bipolar Mania
NCT06462612Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Lumateperone 42 mg with Placebo (2 arms). Primary endpoint: Young Mania Rating Scale at 3 weeks. Started Jul 2024; status: completed.
02
Drugs
lumateperone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT06462612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462612.